{"filing":{"accession_number":"0001213900-26-083961","cik":"0001711754","ticker":"INMB","company_name":"Inmune Bio, Inc.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"ea0300069-8k_inmune.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026083961/ea0300069-8k_inmune.htm"},"events":[{"id":22823,"run_id":20659,"accession_number":"0001213900-26-083961","anchor_item_number":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"INmune Bio received approximately $4.6 million in combined R\u0026D cash rebates from Australia ($4.2M) and the United Kingdom ($0.4M) through government incentive programs. The company explicitly states these \"non-dilutive\" proceeds \"strengthen our financial position\" and \"extend our runway,\" and notes that the combined rebates exceeded net cash used in operating activities during Q2. This is a material financial event affecting the company's liquidity and cash runway, but does not fit a specific named category—it is neither a debt issuance, dividend distribution, nor impairment, making it appropriately classified as financial_other.","company_name":"Inmune Bio, Inc.","ticker":"INMB","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":22890,"accession_number":"0001213900-26-083961","item_number":null,"item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"INmune Bio received approximately $4.6 million in combined R\u0026D cash rebates from Australia ($4.2M) and the United Kingdom ($0.4M) through government incentive programs. The company explicitly states these \"non-dilutive\" proceeds \"strengthen our financial position\" and \"extend our runway,\" and notes that the combined rebates exceeded net cash used in operating activities during Q2. This is a material financial event affecting the company's liquidity and cash runway, but does not fit a specific named category—it is neither a debt issuance, dividend distribution, nor impairment, making it appropriately classified as financial_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:32:08.239798+00:00","company_name":"Inmune Bio, Inc.","ticker":"INMB","filing_date":"2026-07-31"}]}